{"url_path":"/sec/sgmo/10-k/2026/item-11","section_key":"item-11","section_title":"Item 11 EXECUTIVE COMPENSATION","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-30","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-022029-index.html","accession_number":"0001628280-26-022029","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-022029-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":105,"has_tables":true,"body_markdown":"ITEM 11 – EXECUTIVE COMPENSATION\n\nThe information required by this item is to be included in our 2026 Proxy Statement under the sections entitled “Executive Compensation” (excluding the information presented under the subheading “Pay Versus Performance”) and “Election of Directors—Director Compensation,” and is incorporated herein by reference, provided that if the 2026 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.\n\n145\n\n[Table of Contents](#i29aeb4416f69482f8f7bc32e0d48731a_7)"}